Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 226

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 226
---
 |

| • |     | reviewing and discussing with management and our independent registered public accounting firm our annual and            
 quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; |

| • |     | reviewing and discussing with management and the Company’s independent registered public accounting firm our 
 internal controls over financial reporting;                                                                  |

| • |     | adopting and overseeing procedures to address complaints received by the Company regarding accounting, internal 
 accounting controls or auditing matters;                                                                        |

| • |     | reviewing, approving and monitoring related party transactions involving directors or executive officers of the 
 Company;                                                                                                        |

| • |     | recommending based upon the Audit Committee’s review and discussions with management and our independent                        
 registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form 10-K; |

| • |     | monitoring the integrity of our financial statements and our compliance with legal, regulatory and ethical 
 requirements as they relate to our financial statements and accounting matters;                            |

| • |     | setting hiring policies with regard to the hiring of employees or former employees of the Company’s 
 independent registered public accounting firm and overseeing the compliance with such policies;     |

| • |     | reviewing and discussing with management and the Company’s independent registered public accounting firm   
 guidelines and policies to identify, monitor, and address enterprise risks, including cybersecurity risks; |

| • |     | preparing the Audit Committee report required by SEC rules to be included in our annual proxy statement; and |

| • |     | reviewing quarterly earnings releases. |

The Audit Committee held five (5) meetings during 2024. A copy of the Audit Committee Charter is available on the Company’s website at www.aadibio.comunder the Investors & News section. Compensation Committee Caley Castelein, Anupam Dalal and Richard Maroun serve on the Compensation Committee, which is chaired by Mr. Maroun. Our board of directors has determined that each member of the Compensation Committee is “independent” as defined in the applicable Nasdaq rules. The Compensation Committee’s responsibilities include:

| • |     | annually reviewing and recommending to the independent directors on the board of directors the corporate goals 
 and objectives relevant to the compensation of our Chief Executive Officer (or Principal Executive Officer);   |

| • |     | evaluating the performance of our Chief Executive Officer (or Principal Executive Officer) in light of such                                                                                                                                
 corporate goals and objectives and based on such evaluation recommending to the independent directors on the board of directors the